Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country
SHANGHAI and HONG KONG,Nov. 28,2024-- Antengene Corporation Limited ("Antengene",SEHK: 6996.HK),a leading innovative,commercial-stage global biopharmaceutical company dedicated to discoveri